BIOCARDIA INC(NASDAQ:BCDA) stock News

BCDA Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: The Motley Fool

BioCardia Narrows Loss in Fiscal Q2

23 days ago - By: BioCardia, Inc.

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

23 days ago - By: Benzinga - Mentions: SPHR ARQ DOLE TELA ...

Earnings Scheduled For August 11, 2025

a year ago - By: Benzinga

Peering Into BioCardia's Recent Short Interest

a month ago - By: BioCardia, Inc.

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

a month ago - By: BioCardia, Inc.

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

a month ago - By: BioCardia, Inc.

BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure

2 months ago - By: BioCardia, Inc.

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

4 months ago - By: BioCardia, Inc.

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

4 months ago - By: BioCardia, Inc.

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

4 months ago - By: BioCardia, Inc.

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

4 months ago - By: BioCardia, Inc.

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

5 months ago - By: Yahoo Finance - Mentions: AZN NFLX TSLA SIGA ...

Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth?

5 months ago - By: BioCardia, Inc.

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

5 months ago - By: BioCardia, Inc.

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

5 months ago - By: BioCardia, Inc.

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

5 months ago - By: BioCardia, Inc.

BioCardia Reports 2024 Business Highlights and Financial Results

6 months ago - By: BioCardia, Inc.

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

6 months ago - By: BioCardia, Inc.

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

6 months ago - By: BioCardia, Inc.

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

7 months ago - By: BioCardia, Inc.

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

7 months ago - By: BioCardia, Inc.

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

9 months ago - By: BioCardia, Inc.

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

9 months ago - By: BioCardia, Inc.

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

10 months ago - By: BioCardia, Inc.

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

10 months ago - By: BioCardia, Inc.

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

a year ago - By: BioCardia, Inc.

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

a year ago - By: BioCardia, Inc.

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

a year ago - By: BioCardia, Inc.

BIOCARDIA INC (BCDA) Stock News

BCDA Latest News, Press Relases and Analysis

BioCardia Narrows Loss in Fiscal Q2

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Earnings Scheduled For August 11, 2025

Peering Into BioCardia's Recent Short Interest

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth?

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

BioCardia Reports 2024 Business Highlights and Financial Results

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules